欢迎来到 CSNpharm! 产品仅用于科研!
首页 400-920-2911

Histone Demethylase

Histone Demethylase

货号 产品名 CAS号 信息
CSN15764 SP-2509 1423715-09-6 SP-2509 is a histone demethylase LSD1 (KDM1A) antagonist with IC50 of 13 nM.
CSN21313 Seclidemstat 1423715-37-0 Seclidemstat is a potent LSD1 inhibitor, with a mean IC50 of 127 nM.
CSN23851 QC6352 1851373-36-8 QC-6352 is a selective inhibitor of KDM4 family with IC50s of 104 nM, 56 nM, 35 nM, and 104 nM for KDM4A, KDM4B, KDM4C and KDM4D respectively.
CSN21131 ORY-1001 (trans) 1431303-72-8 ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor.
CSN16347 ORY-1001 1431326-61-2 ORY-1001 is a selective inhibitor of lysine-specific demethylase LSD1/KDM1A with IC50 of < 20 nM.
CSN17182 OG-L002 1357302-64-7 OG-L002 is a selective inhibitor of LSD1 with IC50 of 20 nM.
CSN19732 NCL-1 2199214-20-3 NCL-1 is a KDM1A-specific inhibitor to promote differentiation and apoptosis of glioma stem cells (GSCs). KDM1A inhibitor modulates several pathways related to stemness, differentiation and apoptosis. it can induce activation of the unfolded protein response (UPR) pathway.
CSN21362 NCGC00247743 1435192-04-3 NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.
CSN21075 NCGC00244536 2003260-55-5 NCGC00244536 is a selective inhibitor of KDM4A with IC50 of 10 nM.
CSN19733 NCD-38 1456907-39-3 NCD-38 is a KDM1A-specific inhibitor to promote differentiation and apoptosis of glioma stem cells (GSCs). KDM1A inhibitor modulates several pathways related to stemness, differentiation and apoptosis. it can induce activation of the unfolded protein response (UPR) pathway.
CSN13837 ML324 1222800-79-4 ML324 is an inhibitor of JMJD2 demethylase with IC50 of 920 nM with antiviral activity.
CSN20246 LPE-1 1637373-70-6 LPE-1 is a histone lysine specific demethylase 1 (LSD1) (IC50=0.336±0.003μM) inhibitor selectively suppressed the viability of esophageal cancer cell line (EC-109) bearing overexpressed LSD1. It can significantly suppressed proliferation, induced apoptosis, arrested cell cycle of EC109 cells at G2/M phase, and caused changes of the associated protein markers correspondingly.
CSN13708 JIB-04 199596-05-9 JIB-04 is a selective inhibitor of jumonji histone demethylase with IC50s of 230/340/855/445/435/1100, and 290 nM for JARID1A/JMJD2E/JMJD3/JMJD2A/JMJD2B/JMJD2C, and JMJD2D, respectively.
CSN12941 IOX1 5852-78-8 IOX1 is the broad-spectrum inhibitor of 2OG oxygenases and its IC50 for KDM4A/KDM3A and KDM4C/KDM6B/KDM2A/KDM4E are 0.6/0.1 μM and 0.6 μM/1.6 μM/1.8 μM/2.3 μM.
CSN13902 GSK2879552 1401966-69-5 GSK2879552 is an irreversible inhibitor of lysine specific demethylase 1 (LSD1) with Ki of 1.7 μM with antineoplastic activity.
CSN19211 GSK2879552 2HCl 1902123-72-1 GSK2879552 dihydrochloride is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
CSN19201 GSK-LSD1 2HCl 1821798-25-7 GSK-LSD1 dihydrochloride is a selective LSD1 inhibitor with IC50 of 16 nM.
CSN17785 GSK-J2 1394854-52-4 GSK-J2 is a pyridine regio-isomer of GSK-J1 which poorly inhibits JMJD3 (IC50 > 100 μM), making it an appropriate negative control for in vitro studies involving GSK-J1 and is a selective inhibitor for human H3K27me3 demethylases.
CSN18962 GSK-J1 Lithium 1373422-39-9 GSK-J1 lithium is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50 = 60 nM for human JMJD3 in vitro).
CSN13832 GSK-J1 1373422-53-7 GSK-J1 is a H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM for JMJD3 (KDM6B) and UTX (KDM6A), respectively.
CSN19181 GSK-J4 HCl 1797983-09-5 GSK J4 is selective inhibitor of jumonji H3K27 demethylase. It can attenuate lipopolysaccharide (LPS)-induced proinflammatory cytokine production.
CSN16348 GSK-J4 1373423-53-0 GSK J4 is a cell permeable prodrug rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor and attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 μM for the inhibition of TNFα release).
CSN18965 DDP-38003 2HCl 1831167-98-6 DDP-38003 dihydrochloride is an orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM.
CSN16898 CPI-455 1628208-23-0 CPI-455 is a selective inhibitor of KDM5 demethylases and can reduce survival of drug-tolerant cancer cells.
CSN19243 CPI-455 HCl 2095432-28-1 CPI-455 HCl is an inhibitor of KDM5. It can elevate global levels of H3K4 trimethylation (H3K4me3) and decrease the number of DTPs in multiple cancer cell line models.
CSN18960 CBB1007 3HCl 2070015-03-9 CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).
CSN17765 CBB1007 1379573-92-8 CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).
CSN18959 CBB1007 HCl 2070014-96-7 CBB1007 hydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).
CSN17764 CBB1003 1379573-88-2 CBB1003 is a histone demethylase LSD1 inhibitor with IC50 of 10.54 μM.
CSN18963 CBB1003 HCl 2070015-02-8 CBB1003 hydrochloride is a histone demethylase LSD1 inhibitor with IC50 of 10.54 μM.
CSN21279 AS-8351 796-42-9 AS8351 is a selective inhibitor of histone demethylase KDM5B (JARID1B) via competing for the chelated iron KDM5B needs and it can act as an iron chelator.
CSN20531 GSK-LSD1 1431368-48-7
<< PREV 1 2 NEXT >>